Comment[ArrayExpressAccession]	E-GEOD-71432
MAGE-TAB Version	1.1					
Public Release Date	2016-08-01
Investigation Title	Circulating microRNA profiles in patients with type-1 autoimmune hepatitis					
Comment[Submitted Name]	Circulating microRNA profiles in patients with type-1 autoimmune hepatitis
Experiment Description	Recent studies have demonstrated that micro (mi)RNA molecules can be detected in the circulation and can serve as potential biomarkers of various diseases. This study used microarray analysis to identify aberrantly expressed circulating miRNAs in patients with type 1 autoimmune hepatitis (AIH) compared with healthy controls. Patients with well-documented and untreated AIH were selected from the National Hospital Organization (NHO)-AIH-liver-network database. They underwent blood sampling and liver biopsy with inflammation grading and fibrosis staging before receiving treatment. To further confirm the microarray data, circulating expression levels of miR-21 and miR-122 were quantified by real-time quantitative polymerase chain reaction in 46 AIH patients, 40 patients with chronic hepatitis C (CHC), and 15 healthy controls. Consistent with the microarray data, serum levels of miR-21 were significantly elevated in AIH patients compared with CHC patients and healthy controls. miR-21 and miR-122 serum levels correlated with alanine aminotransferase levels. Circulating levels of miR-21 and miR-122 were significantly reduced in AIH patients with liver cirrhosis, and were inversely correlated with increased stages of fibrosis. By contrast, levels of circulating miR-21 showed a significant correlation with the histological grades of inflammation in AIH. We postulate that aberrantly expressed serum miRNAs are potential biomarkers of AIH and could be implicated in AIH pathogenesis. Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH. Case-control study, steroid treatment					
Term Source Name	ArrayExpress	EFO
Term Source File	http://www.ebi.ac.uk/arrayexpress/	http://www.ebi.ac.uk/efo/efo.owl				
Person Last Name	Kondo	Migita				
Person First Name	Satoshi	K				
Person Email	Satoshi_Kondou@nts.toray.co.jp					
Person Affiliation	Toray Industries,Inc.					
Person Address	New Projects Development Division, Toray Industries,Inc., Tebiro 6-10-1, Kamakura, Kanagawa, Japan					
Person Roles	submitter					
Protocol Name	P-GSE71432-1	P-GSE71432-4	P-GSE71432-5	P-GSE71432-2	P-GSE71432-3	P-GSE71432-6
Protocol Description	The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals. ID_REF =  VALUE = Normalized signal intensity	Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray, Kamakura, Japan)	Hybridized for 16 h at 37 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..	Steroid treatment	RNA samples were extracted using miRNesy mini kit (Qiagen).	3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).
Protocol Type	normalization data transformation protocol	labelling protocol	hybridization protocol	sample treatment protocol	nucleic acid extraction protocol	array scanning protocol
Experimental Factor Name	treatment	disease state				
Experimental Factor Type	treatment	disease state				
Comment[SecondaryAccession]	GSE71432					
Comment[GEOReleaseDate]	2016-08-01					
Comment[ArrayExpressSubmissionDate]	2015-07-28					
Comment[GEOLastUpdateDate]	2016-08-02					
Comment[AEExperimentType]	transcription profiling by array					
SDRF File	E-GEOD-71432.sdrf.txt